A research team led by the University of California, Irvine has discovered the key role that the APOBEC3A and APOBEC3B enzymes play in driving cancer mutations by modifying the DNA in tumor genomes, offering potential new ...
Mar 19, 2024
0
60
A cellular profiling method called dynamic BH3 profiling (DBP), developed by investigators at Dana-Farber Cancer Institute, has the potential to help guide personalized treatment for relapsed, drug-resistant acute myeloid ...
Mar 6, 2024
0
0
A novel PET imaging tracer has been proven to safely and effectively detect a common cancer gene mutation that is an important molecular marker for tumor-targeted therapy. By identifying this mutation early, physicians can ...
Dec 20, 2023
0
2
A proportion of patients with drug-resistant tuberculosis (TB) receive ineffective treatment due to misdiagnosis by rapid molecular tests, according to a genomic analysis carried out in southern Mozambique and co-led by the ...
Dec 4, 2023
0
8
Mutations in a genetic region that regulates RNA stability could influence prostate cancer outcomes and drug resistance, according to new work from scientists at Fred Hutchinson Cancer Center published in Cell Reports.
Aug 7, 2023
0
65
More than 70 FDA-approved cancer drugs are kinase inhibitors, which work by blocking kinases—enzymes that add phosphate groups to molecules in the cell—and preventing the chemical activity necessary for signaling and ...
Feb 13, 2023
0
56
In Brazil, a group of researchers has reported the largest outbreak to date of COVID-associated candidemia caused by the same drug-resistant strain of Candida parapsilosis, a fungus that invades the bloodstream and can lead ...
Nov 30, 2022
0
15
One of the greatest challenges facing cancer researchers is to understand why some patients don't respond to treatments. In some cases, tumors exhibit what is known as multidrug resistance (MDR), which significantly limits ...
Jul 22, 2022
0
152
A combination of up to five drugs normally used to treat conditions ranging from HIV to Type 2 diabetes could destroy cancer cells, yet be less toxic than a chemotherapy drug used for recurring ovarian cancer.
Jul 14, 2022
0
35
Imatinib, better known as Gleevec, was hailed as a "miracle" cancer drug when it entered the market in the early 2000s. Though it has been highly successful at treating early-stage chronic myeloid leukemia (CML)—a rare ...
Jun 1, 2022
0
150
